Special Drug Use Investigation of EYLEA for Central Retinal Vein Occlusion (CRVO)
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion
- Focus Adverse reactions
- Acronyms JPMS-CRVO
- Sponsors Bayer
- 05 Mar 2019 Status changed from active, no longer recruiting to completed.
- 17 Mar 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019 as per ClinicalTrails.gov record.
- 18 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.